Octreotide (CAS 79517-01-4) is a high-purity, pharmaceutical-grade Somatostatin Analog synthesized via advanced solid-phase peptide synthesis, fully complying with USP and EP quality standards. Its molecular structure mimics natural somatostatin but with enhanced stability and longer half-life, enabling it to selectively inhibit the secretion of growth hormone, gastrin, and other gastrointestinal hormones. Produced with strict control over peptide purity (≥99%) and biological activity, each batch undergoes rigorous functional assays, making it a reliable raw material for hormone-regulating and anti-tumor drug formulation.
This potent peptide analog stands out for its multifunctional therapeutic effects: it effectively manages acromegaly by reducing excess growth hormone levels, controls symptoms of neuroendocrine tumors (such as carcinoid syndrome), and treats severe diarrhea and fistulas caused by gastrointestinal disorders. Unlike broad-spectrum hormone inhibitors, it targets specific hormone-secreting cells with high selectivity, minimizing systemic side effects and supporting long-term clinical use. Its stable structure supports formulation into injectable solutions and long-acting depot preparations, catering to diverse treatment schedules.
Octreotide (CAS 79517-01-4) caters to professional users: pharmaceutical manufacturers developing endocrine and oncology medications, specialty clinics, and research institutions studying hormone regulation. Its clinically proven efficacy, pharmaceutical-grade purity, and targeted mechanism make it a top choice for buyers prioritizing reliability and therapeutic versatility. Whether for large-scale commercial production or preclinical research, this Somatostatin Analog meets the stringent demands of the global endocrine and oncology pharmaceutical sectors.
